Name:
Institution:
Type:
PI
Grant Award Details
Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy
Grant Number:
DISC2P-11946
Project Objective:
- The objective is to validate a stem cell-based microphysiological system (MPS) for predicting cardiac toxicity, including modeling drug-drug interactions in polytherapy for the treatment of SARS-CoV-2 in patients with diverse backgrounds
Investigator:
Disease Focus:
COVID-19
Infectious Disease
Human Stem Cell Use:
iPS Cell
Award Value:
$224,500
Status:
Closed
Progress Reports
Reporting Period:
Year 1
View Report
Grant Application Details
Application Title:
- Safety “Clinical Trial” of the Cardiac Liability of COVID19 Polytherapy
Public Abstract:
Statement of Benefit to California:
Publications
- Clin Transl Sci (2021) In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. (PubMed: 33786981)
- Front Pharmacol (2021) Heart Muscle Microphysiological System for Cardiac Liability Prediction of Repurposed COVID-19 Therapeutics. (PubMed: 34421592)
- bioRxiv (2020) In Vitro Safety "Clinical Trial" of the Cardiac Liability of Hydroxychloroquine and Azithromycin as COVID19 Polytherapy. (PubMed: 33398282)
